Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology & Drugs -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (110)	7/12/2002 3:57:03 PM
From: SusieQ1065	Respond to of 232

09:07 ET Merrill Lynch says positive changes at FDA should benefit biotechs Merrill Lynch believes that impending changes at the FDA should help to improve investor psychology with respect to the FDA and biotech; recent meeting with Biotechnology Industry Organization leads firm to conclude: 1) PDUFA III should reduce review times and increase the predictability at the FDA; 2) FDA commissioner should be nominated shortly, whom the biotech industry should find amenable; and 3) generic biologics likely will not be available without co's having to conduct phase II studies, at a minimum. In addition, firm cites attractive valuations in biotechs as well as historically good performance in 2nd half of the year.